Targeted therapy plus hormone therapy for early HER2-positive breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether adding a targeted therapy (a CDK4/6 inhibitor) to standard hormone therapy can let some people safely skip chemotherapy. It is for early-stage, hormone-positive breast cancer that is also HER2-positive, and aims to reduce side effects while keeping the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have had surgery to remove an early-stage breast cancer that is smaller than 2 cm and has not spread to lymph nodes.
- Your cancer is strongly hormone-receptor positive (estrogen receptor at least 50%).
- Your cancer tests positive for HER2 (a protein that helps cancer grow) — either strongly positive (3+) or weakly positive with a gene test confirming it.
- Your cancer is a low or intermediate grade, or if it's high grade, it must be a luminal type or very small (1 cm or less).
- Your heart, blood, liver, and kidney function are within acceptable ranges, and you have not had previous cancer treatment for this disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
This trial tests a combination of three HER2-targeted drugs with a CDK4/6 inhibitor before surgery for breast cancer that is both HER2-positive and ER-positive. It aims to see if this approach shrinks tumors more effectively and is safe.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This trial is testing a new treatment plan for women with high-risk breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-). It combines radiation therapy after surgery with a CDK4/6 inhibitor, which is a targeted therapy that helps stop cancer cells from dividing. The goal is to see if this combination is safe and well-tolerated, and it may help lower the chance of cancer coming back.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.